1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,555 | 0,925 | 09.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | Arecor Therapeutics - Result of AGM | - | RNS | ||
| 21.05. | Arecor Therapeutics grants 455,000 stock options to executives | 1 | Investing.com | ||
| ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.05. | Arecor Therapeutics - Grant of options and PDMR dealing | - | RNS | ||
| 18.05. | Arecor Therapeutics - Upcoming conference attendance | - | RNS | ||
| 28.04. | Arecor Therapeutics - Posting of Annual Report and Notice of AGMm | - | RNS | ||
| 13.04. | Arecor Therapeutics swings to annual profit; hails insulin product | 4 | Alliance News | ||
| 13.04. | Arecor Therapeutics - Final Results | 3 | RNS | ||
| 30.03. | Arecor Therapeutics - Notice of FY25 Results | - | RNS | ||
| 26.03. | Arecor erhält Meilensteinzahlung von 0,5 Mio. US-Dollar aus Vereinbarung mit Ligand | 1 | Investing.com Deutsch | ||
| 26.03. | Arecor receives $0.5m milestone from Ligand deal | 1 | Investing.com | ||
| 26.03. | Arecor Therapeutics - Ligand Pharmaceuticals Milestone Payment | - | RNS | ||
| 09.03. | Arecor Therapeutics - Arecor to present at Oppenheimer conference | - | RNS | ||
| 09.02. | Arecor Therapeutics revenue falls after Tetris Pharma operations cease | 1 | Alliance News | ||
| 09.02. | Arecor's ultra-concentrated insulin advances with Sequel partnership | 2 | Investing.com | ||
| 09.02. | Arecor treibt ultrakonzentriertes Insulin durch Partnerschaft mit Sequel voran | 1 | Investing.com Deutsch | ||
| 09.02. | Arecor Therapeutics - 2025 Business Update | - | RNS | ||
| 25.09.25 | Arecor Therapeutics PLC: Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 | 206 | GlobeNewswire (Europe) | This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc("Arecor" or the "Company")... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 133,57 | 0,00 % | AbbVie-Aktie: Apogee-Übernahme beflügelt | Die AbbVie-Aktie hat den Wegfall des einstigen Blockbusters Humira deutlich besser verkraftet als viele Anleger erwartet hatten. Mit der milliardenschweren Übernahme von Apogee Therapeutics will der... ► Artikel lesen | |
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| ERASCA | 19,180 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RELAY THERAPEUTICS | 20,750 | 0,00 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein | ||
| VIRAX BIOLABS GROUP | 6,340 | -0,31 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,470 | -0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,15 | +0,02 % | Tarsus Acquires iRenix Medical To Expand Eye Care Pipeline With Late-Stage IRX-101 | ||
| ENLIVEN THERAPEUTICS | 52,18 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| BEAM THERAPEUTICS | 35,840 | +0,06 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,420 | -0,07 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| ABSCI | 11,465 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VOR BIOPHARMA | 19,750 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 48,380 | +0,06 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| TYRA BIOSCIENCES | 33,010 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| TANGO THERAPEUTICS | 30,520 | 0,00 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
Das Unternehmen ARECOR THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARECOR THERAPEUTICS PLC finden Sie auf Wallstreet Online.